Home Featured Page 52

Featured

Latest

Mike Finoia – The Comedy of Conscious Aging, Episode 16

Breaking: Definium Lands Positive Phase 3, LSD Candidate Shows Strong Antidepressant Effect

The Psychedelic Practitioner Issue 5: Groups in Practice

Psychedelic Policy Briefing: Week of June 16, 2026

Psilocybin Compassionate Use in Germany: Lea Mertens and Andrea Jungaberle on the First Patients, Payers and Practicalities

Pioneering Psychedelic Policy: Nevada’s Senate Bill 242 and Beyond

Vital 4: Informational Session and Q+A, with Diego

Vital 4: Informational Session and Q+A, with Johanna

Jungian Psychology, Psychedelics, and the Multiplicity of Self

Psychedelic Funding Update: Q2 2024

What is Spiritual Emergence and How Does it Relate to Psychedelics?

Exploring the Fungal Kingdom: Cultivation, Connection, and the Potential of Permaculture

Pα+ Psychedelic Bulletin #169: Brin Backs Soneira, But Patent Questions Loom...

Psychedelics in Palliative Care: Screening, Safety Measures, and Experiences With the...

When Data Meets Doubt: Investigating the FDA Panel’s Rejection of MDMA

EDITOR PICKS

Mike Finoia – The Comedy of Conscious Aging, Episode 16

Breaking: Definium Lands Positive Phase 3, LSD Candidate Shows Strong Antidepressant...

The Psychedelic Practitioner Issue 5: Groups in Practice

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

ABOUT US

PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.

Featured

Mike Finoia – The Comedy of Conscious Aging, Episode 16

Breaking: Definium Lands Positive Phase 3, LSD Candidate Shows Strong Antidepressant Effect

The Psychedelic Practitioner Issue 5: Groups in Practice

Psychedelic Policy Briefing: Week of June 16, 2026

Psilocybin Compassionate Use in Germany: Lea Mertens and Andrea Jungaberle on the First Patients, Payers and Practicalities

Pioneering Psychedelic Policy: Nevada’s Senate Bill 242 and Beyond

Vital 4: Informational Session and Q+A, with Diego

Vital 4: Informational Session and Q+A, with Johanna

Jungian Psychology, Psychedelics, and the Multiplicity of Self

Psychedelic Funding Update: Q2 2024

What is Spiritual Emergence and How Does it Relate to Psychedelics?

Exploring the Fungal Kingdom: Cultivation, Connection, and the Potential of Permaculture

Pα+ Psychedelic Bulletin #169: Brin Backs Soneira, But Patent Questions Loom...

Psychedelics in Palliative Care: Screening, Safety Measures, and Experiences With the...

When Data Meets Doubt: Investigating the FDA Panel’s Rejection of MDMA

EDITOR PICKS

Mike Finoia – The Comedy of Conscious Aging, Episode 16

Breaking: Definium Lands Positive Phase 3, LSD Candidate Shows Strong Antidepressant...

The Psychedelic Practitioner Issue 5: Groups in Practice

POPULAR POSTS

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

POPULAR CATEGORY